Experimental cell therapy trial offers hope for transplant patients with Treatment-Resistant complications
NCT ID NCT06991361
Summary
This early-stage trial is testing whether a single infusion of specially grown immune cells (EVE-Treg cells) combined with daily low-dose interleukin-2 medication can help control chronic graft-versus-host disease that hasn't responded to standard steroid treatment. The study will enroll 21 children and adults who developed this serious complication after a stem cell transplant for blood cancers. Researchers will primarily assess the safety of this combination approach in patients whose condition hasn't improved with current therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE (CGVHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.